Adma Biologics, INC.: management transactions · United States · SEC (Form 4)

About Adma Biologics, INC.

ADMA Biologics, Inc. is a U.S.-listed biopharmaceutical company traded on the Nasdaq (NASDAQ: ADMA) in the United States, with core operations in New Jersey and Florida. For international investors, the name sits squarely in the Health & Pharma sector, more specifically in plasma-derived biologics and immune globulin therapies. ADMA describes itself as an end-to-end commercial biopharmaceutical company, meaning it participates across development, manufacturing, commercialization, and part of the supply chain for its own products. The company’s strategic niche is attractive: it focuses on specialized therapies for immunocompromised patients and other populations at risk for certain infectious diseases, rather than broad mass-market pharmaceuticals. Founded on June 24, 2004, ADMA has spent two decades building an integrated platform around plasma-based medicines. ADMA’s approved commercial portfolio consists of three FDA-licensed products: ASCENIV, BIVIGAM, and NABI-HB. ASCENIV is the key growth engine and has recently driven the company’s revenue acceleration, supported by stronger physician adoption, broader payer access, and continued patient demand. BIVIGAM remains part of the core franchise, while NABI-HB provides additional exposure to hepatitis B immune globulin. Beyond the marketed portfolio, ADMA is also advancing SG-001, a preclinical pipeline program aimed at broader pneumococcal serotype coverage. While still early-stage, this program gives the company longer-dated optionality beyond its current commercial base. A major part of the investment case is ADMA’s operating model. The company emphasizes vertical integration through its headquarters in Ramsey, New Jersey, its manufacturing campus in Boca Raton, Florida, a plasma collection network under corporate umbrella, and a reported plasma fractionation and purification capacity of up to roughly 600,000 liters annually. That control over raw material sourcing and manufacturing is strategically important in plasma-derived therapeutics, where supply visibility, quality control, and regulatory compliance can materially affect margins and product availability. ADMA also highlights CDMO capabilities and fill-finish capacity, which could support future diversification. Recent news flow has been constructive. In February 2026, ADMA reported record full-year 2025 results, including revenue of $510.2 million, up 20% year over year, and gross margin of 57.4%. Management also guided to further growth in 2026 and 2027 and reiterated a longer-term target above $1.1 billion in annual revenue by 2029. In March 2026, the company announced a $125 million accelerated share repurchase as part of a planned $200 million 2026 buyback initiative, underscoring management’s confidence and a more shareholder-friendly capital allocation posture. Overall, ADMA offers investors a mix of specialty biopharma growth, industrial execution, and margin expansion potential, with regulatory and commercial milestones remaining central to the story.